Background
Coronavirus disease 2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which has spread around the world [
1]. Till September 09, 2020, the SARS-CoV-2 has infected over 27 million people and caused over 890,000 deaths [
2]. The severity of COVID-19 may be strongly related to the immune status of patients, but this is poorly understood. Therefore, it is necessary to investigate the association of immunological features with COVID-19 severity, which may help identify immune markers for effective triage of COVID-19 patients.
Although some studies have focused on the association between immunologic features and COVID-19 severity, the conclusions remain controversial. Chen et al. found that the SARS-CoV-2 infection can decrease the counts of T lymphocytes, particularly CD4
+ and CD8
+ T cells [
3]. Qin et al. showed that the cytokines of severe COVID-19 cases, such as tumor necrosis factor alpha (TNF-α), interleukin-5 (IL-5), IL-6 and IL-10, increased during the COVID-19 progression [
4]. Sophie et al. demonstrated that the increased serum concentrations of IFN-γ inducible protein-10 (IP-10) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were associated with day-28 mortality of COVID-19 patients [
5]. However, other studies have revealed that CD4
+ and CD8
+ T cells [
4], some cytokines (IL-5, IL-6 and IL-10) [
6] and chemokines (GM-CSF and IP-10) [
7] showed no significant differences between severe cases and mild cases. Thus, we presented a meta-analysis of 21 studies in order to assess the association between immune cells (CD3
+ T, CD4
+ T, CD8
+ T, Treg, B and NK cells), cytokines (TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-6 and IL-10), chemokines (GM-CSF, RANTES, MCP-1, IP-10 and eotaxin) and COVID-19 severity respectively.
Methods
Search strategy
We performed a systematic literature search to identify relevant studies published up to September 09, 2020 in PubMed, Web of Science, Scopus, the Cochrane Library and the grey literature. The following combined search terms were used: (“Novel coronavirus” OR “Coronavirus disease 2019” OR “Coronavirus 2019” OR “nCoV-2019” OR “2019-nCoV” OR “COVID-19” OR “SARS-CoV-2”) and ((“CD3+ T” OR “CD4+ T” OR “CD8+ T” OR “CD4+/CD8+” OR “Treg” OR “B cell” OR “NK cell”) OR (“interferon gamma” OR “tumor necrosis factor alpha” OR “IL-2” OR “IL-4” OR “IL-5” OR “IL-6” OR “IL-10”) OR (“chemokine” OR “chemokines” OR “RANTES” OR “GM-CSF” OR “Eotaxin” OR “MCP-1” OR “IP-10”)).
Study selection
Inclusion criteria of the study were as follows: 1) studies with data on immune cells (CD4+ T, CD8+ T, CD3+ T, CD4+/CD8+, Treg, B and NK cells), cytokines (IFN, TNF-α, IL-2, IL-4, IL-5, IL-6 and IL-10) and chemokines (GM-CSF, RANTES, MCP-1, IP-10 and eotaxin) with mean ± standard deviation (SD) or median (interquartile range, IQR); 2) patients could be grouped into severe cases and mild cases; and 3) studies with clear information on COVID-19 confirmation and included patients. The exclusion criteria were as follows: 1) studies without corresponding outcome of indicators; 2) studies without available full texts; 3) studies not published in English; 4) lack of mean ± SD or mean (IQR) of indicators; 5) reviews, editorials, case reports, and meta-analyses.
Two investigators developed the search strategy and one investigator conducted the primary systematic search for all studies meeting the predetermined inclusion criteria. The titles and abstracts of the retrieved articles were screened for duplication and relevance to the topic. A second investigator assessed study eligibility, quality assessment, and data extraction, for validity and consistency. Full-text reports of the identified citations were reviewed by both the primary and secondary investigators in order to select the final studies. All discrepancies were resolved by consensus, and if necessary, by consultation with the third investigator.
The following data were extracted from each study: 1) the first author and year of publication; 2) study design; 3) the country where the study was conducted; 4) age; 5) sample size; 6) sex; 7) the levels of immune cells (CD4
+ T, CD8
+ T, CD3
+ T, CD4
+/CD8
+, Treg, B and NK cells), and cytokines (IFN, TNF-α, IL-2, IL-4, IL-5, IL-6 and IL-10), and chemokines (GM-CSF, RANTES, MCP-1, IP-10 and eotaxin). Median (IQR) values were converted to mean ± SD using mathematical formulas as reported by Hozo et al. [
8].
Quality assessment
Quality assessments of the studies were carried out based on the Newcastle-Ottawa Scale (NOS). The total NOS score ≥ 7 indicated a good research quality of the included study.
Data synthesis and analysis
Data entry and analysis were performed with Review Manager 5.3 (The Cochrane Collaboration, Oxford, England). Heterogeneity within each group of studies was assessed by Q test and I2 statistics. A random-effects model was used when I2 > 50% or p < 0.05 and a fixed-effects model was used when I2 ≤ 50% or p ≥ 0.05. For the continuous data, we calculated mean differences (MD) and 95% confidence intervals (CI) between severe cases and mild cases. To investigate the potential publication bias, we visually examined the funnel plots. To assess the robustness of the results, we performed sensitivity analyses by removing one study at a time.
Discussion
It is necessary to investigate the host immune response to SARS-CoV-2, which may help identify immune markers of disease severity for effective triage of COVID-19 patients [
11]. Our study compared the levels of immune cells, cytokines and chemokines between mild and severe COVID-19 patients.
The variations of immune cell levels are inconsistent among different reports. The majority of our included studies reported significantly lower levels of immune cells (CD3
+ T, CD8
+ T, CD4
+ T, B and NK cells) in severe cases compared with mild cases [
3,
12,
13]. Only two studies didn’t find significant reductions in CD8
+ T cells [
4,
14], while one study reported an increase of B cell [
15] in severe cases. Using all the collected evidence, our meta-analysis results found that the decrease in CD3
+ T, CD8+ T, CD4+ T, B and NK cells was significant in severe cases, but Treg cells and the ratio of CD4
+/CD8
+ T cells showed no significant difference.
The mechanism underlying the reduction of immune cell levels and COVID-19 severity remains to be determined. CD8
+ T cells exert their effects mainly through two mechanisms, including cytolytic activity against target cells and cytokine secretion [
16]. CD4
+ T cells are capable of activating the CD8
+ T cell response to acute respiratory virus infection [
11]. SARS-CoV-2 and associated autoimmune antibodies may contribute to the growth inhibition and apoptosis of immune cells [
6,
17].
The cytokine variations of various studies are also inconsistent. Except for one study on IL-6 [
6] and another study on TNF-α, most of our included studies reported that IL-6 and TNF-α levels were significantly higher in severe cases compared with mild cases [
4,
16,
18,
19]. Some of our included studies found no significant difference in the levels of IL-2, IL-4, IL-5, and IFN-γ, while almost an equivalent number of studies of each indicator found that they were significantly higher in severe cases. Synthesizing all the collected evidence, our meta-analysis results found that IL-5, IL-6, IL-10 and TNF-α levels were significantly higher in severe cases compared with mild cases. However, the levels of IL-2, IL-4, IFN-γ, Treg cells and CD4
+/CD8
+ ratios showed no significant differences.
In severely infected individuals, SARS-CoV-2 could induce an excessive cytokine response, such as IL-6, IL-10, and TNF-α surge, known as cytokine storm. Cytokine storms may contribute to acute respiratory distress syndrome (ARDS) or multiple-organ dysfunction, resulting in physiological deterioration and death [
20]. Cytokines such as IL-10, IL-6, and TNF-α are also involved in the decline of T cell counts. IL-6 contributes to host defense by stimulating acute phase responses [
21]. TNF-α is a pro-inflammatory cytokine that can promote T cell apoptosis [
22]. Patients requiring ICU admission have significantly higher levels of IL-6, IL-10, and TNF-α. Further, the levels of IL-6, IL-10, and TNF-α inversely correlate with CD4
+ and CD8
+ T cell counts [
23]. This fact is strengthened by our meta-analysis results.
SARS-CoV-2 infection is a potent inducer of proinflammatory chemokines that are potentially involved in the defense against viral infection [
10]. Some studies have reported higher concentrations of GM-CSF [
5], IP-10 [
5,
10,
24], MCP-1 [
10,
24], eotaxin [
7] and RANTES [
24] between severe cases and mild cases. However, other studies have not revealed significant differences in the concentrations of GM-CSF [
7,
10], IP-10 [
7], RANTES [
10], MCP-1 [
7], and eotaxin [
10] . Synthesizing all the collected evidence, our meta-analysis results found that MCP-1, IP-10 and eotaxin levels were significantly higher in severe cases compared with mild cases. However, levels of GM-CSF and RANTES showed no significant differences. Binding to the chemokine receptor 3, IP-10 activates and recruits leucocytes, including T cells and monocytes [
25]. MCP-1-mediated migration of monocytes from the blood stream through the vascular endothelium is essential for routine immune surveillance in tissues in response to inflammation [
26]. Abnormally elevated MCP-1, IP-10 and eotaxin levels may help to determine the severity of SARS-CoV-2 infections and serve as prognostic markers for disease progression.
Cytokines and chemokines play a key role in the pathogenesis of ARDS. After SARS-CoV-2 infection, vascular endothelial cells become dysfunctional and IL-6, TNF-a, and MCP-1 levels are elevated, leading to COVID-19-associated vascular inflammation and coagulopathy, particularly endotheliitis in the lungs, heart and kidney [
27,
28]. TNF-a is central in the pathogenesis of inflammation and triggers the release of many inflammatory mediators including IL-1, IL-6, IL-8, and GM-CSF [
29]. TNF-a can also disintegrate the endothelial and epithelial cytoskeleton, resulting in alveolar-capillary barrier disruption, vascular leakage and alveolar edema, which in turn leads to hypoxia in the body [
30].
Limitations
Several limitations of our study should be considered. Firstly, the number of studies and participants was not large enough for publication bias analysis of most indicators. Secondly, the majority of the included studies in this meta-analysis were retrospectives. Thirdly, the overall generalizability of the meta-analysis results should be interpreted with caution as most of the included studies were conducted in China due to limitations in geographic distribution and ethnic diversity. It would be better to include more studies with a broad geographic scope to gain a more comprehensive understanding of the immunological features of COVID-19 patients.
Conclusions
Our synthesized results revealed significantly lower levels of immune cells in CD3+ T, CD4+ T, CD8+ T, B and NK cells, higher levels of cytokines (TNF-α, IL-5, IL-6 and IL-10) and higher levels of chemokines (MCP-1, IP-10 and eotaxin) in severe cases compared with mild cases of COVID-19. However, there was no significant difference in levels of Treg cell, the ratio of CD4+/CD8+ T cell, IL-2, IL-4, IFN-γ, GM-CSF and RANTES. Measurement of immune cells and cytokines may help identify immune markers of COVID-19 severity and contribute to the development of immunologic therapies and vaccines.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.